M.B. Hesselink

1.1k total citations
30 papers, 955 citations indexed

About

M.B. Hesselink is a scholar working on Cellular and Molecular Neuroscience, Molecular Biology and Psychiatry and Mental health. According to data from OpenAlex, M.B. Hesselink has authored 30 papers receiving a total of 955 indexed citations (citations by other indexed papers that have themselves been cited), including 24 papers in Cellular and Molecular Neuroscience, 16 papers in Molecular Biology and 8 papers in Psychiatry and Mental health. Recurrent topics in M.B. Hesselink's work include Neuroscience and Neuropharmacology Research (15 papers), Neurotransmitter Receptor Influence on Behavior (15 papers) and Receptor Mechanisms and Signaling (10 papers). M.B. Hesselink is often cited by papers focused on Neuroscience and Neuropharmacology Research (15 papers), Neurotransmitter Receptor Influence on Behavior (15 papers) and Receptor Mechanisms and Signaling (10 papers). M.B. Hesselink collaborates with scholars based in Netherlands, Germany and United Kingdom. M.B. Hesselink's co-authors include Wojciech Danysz, D. D. Breimer, G. Quack, Chris G. Parsons, Eberhard Fuchs, Boldizsár Czéh, Barthel Schmelting, Mária Simon, Wojciech Danysz and Andrew C. McCreary and has published in prestigious journals such as Brain Research, Journal of Medicinal Chemistry and Journal of Pharmacology and Experimental Therapeutics.

In The Last Decade

M.B. Hesselink

30 papers receiving 918 citations

Peers

Countries citing papers authored by M.B. Hesselink

Since Specialization

Citations

This map shows the geographic impact of M.B. Hesselink's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by M.B. Hesselink with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites M.B. Hesselink more than expected).

Fields of papers citing papers by M.B. Hesselink

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by M.B. Hesselink. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by M.B. Hesselink. The network helps show where M.B. Hesselink may publish in the future.

Co-authorship network of co-authors of M.B. Hesselink

This figure shows the co-authorship network connecting the top 25 collaborators of M.B. Hesselink. A scholar is included among the top collaborators of M.B. Hesselink based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with M.B. Hesselink. M.B. Hesselink is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	SONU20176289, a compound combining partial dopamine D2 receptor agonism with specific serotonin reuptake inhibitor activity, affects neuroplasticity in an animal model for depression 2008 ·European Journal of Pharmacology ·Adina T. Michael‐Titus, (unknown), Gregory J. Michael, Thomas Michaelis, Takashi Watanabe, Jens Frahm, (unknown), Marieke G. C. van der Hart, M.B. Hesselink, Eberhard Fuchs, Boldizsár Czéh	13
2	Multi-modal characterisation of the neocortical clip model of focal cerebral ischaemia by MRI, behaviour and immunohistochemistry 2007 ·Brain Research ·(unknown), John S. Beech, Andrew Lowe, M.B. Hesselink, Michel Modo, Steven Williams	33
3	In vitro characterization of SLV308 (7-[4-methyl-1-piperazinyl]-2(3H)-benzoxazolone, monohydrochloride): A novel partial dopamine D2 and D3 receptor agonist and serotonin 5-HT1A receptor agonist 2006 ·Synapse ·Jeffrey Glennon, (unknown), Eric Ronken, M.B. Hesselink, (unknown), (unknown), Stephen Long, (unknown), Andrew C. McCreary	33
4	No nerve growth factor response to treatment with memantine in adult rats 2004 ·Journal of Neural Transmission ·Undine E. Lang, (unknown), M.B. Hesselink, Wojciech M. Zajączkowski, Wojciech Danysz, Heidi Danker‐Hopfe, Rainer Hellweg	13
5	Chronic Stress Decreases the Number of Parvalbumin-Immunoreactive Interneurons in the Hippocampus: Prevention by Treatment with a Substance P Receptor (NK1) Antagonist 2004 ·Neuropsychopharmacology ·Boldizsár Czéh, Mária Simon, (unknown), Barthel Schmelting, M.B. Hesselink, Eberhard Fuchs	113
6	Tonic inhibition by orphanin FQ/nociceptin of noradrenaline neurotransmission in the amygdala 2003 ·European Journal of Pharmacology ·Yukie Kawahara, M.B. Hesselink, (unknown), Ben H.C. Westerink	31
7	DU127090: A novel partial dopamine agonist with antipsychotic activity partial agonist character in functional assays in vivo 2003 ·Schizophrenia Research ·(unknown), M.B. Hesselink, S.K. Long, (unknown), J. Arnt, Michael Didriksen, (unknown)	1
8	SLV313 is a dopamine D2 receptor antagonist and serotonin 5-HT1A receptor agonist: In vitro and in vivo neuropharmacology 2002 ·European Neuropsychopharmacology ·Jeffrey Glennon, Andrew C. McCreary, Eric Ronken, Richard J. Siarey, M.B. Hesselink, (unknown), (unknown), S.K. Long, (unknown)	9
9	SLV310, a molecule combining potent dopamine D2 receptor antagonism with serotonin reuptake inhibition: In vitro and in vivo neurochemistry 2001 ·European Neuropsychopharmacology ·M.B. Hesselink, (unknown), Chris G. Kruse, S.K. Long	2
10	SLV310, a molecule combining potent dopamine D2 receptor antagonism with serotonin reuptake inhibition, active in preclinical models for antipsychotic as well as anxiolytic activity 2001 ·European Neuropsychopharmacology ·(unknown), Arnoud H. J. Herremans, J.A.M. van der Heyden, Andrew C. McCreary, M.B. Hesselink, Chris G. Kruse, S.K. Long	4
11	Extracellular Concentrations of Taurine, Glutamate, and Aspartate in the Cerebral Cortex of Rats at the Asymptomatic Stage of Thioacetamide-Induced Hepatic Failure: Modulation by Ketamine Anesthesia 2000 ·Neurochemical Research ·Jan Albrecht, Wojciech Hilgier, Magdalena Zielińska, (unknown), M.B. Hesselink, (unknown)	20
12	Brain distribution of an uncompetitive NMDA receptor antagonist; comparison to its in vitro potency in electrophysiological studies 1999 ·Naunyn-Schmiedeberg s Archives of Pharmacology ·M.B. Hesselink, Chris G. Parsons, (unknown), Wojciech Danysz	11
13	Dopamine release in the prefrontal cortex in response to memantine following sub-chronic NMDA receptor blockade with memantine: a microdialysis study in rats 1999 ·Journal of Neural Transmission ·M.B. Hesselink, Albertus G. de Boer, D. D. Breimer, Wojciech Danysz	27
14	Brain Penetration and In Vivo Recovery of NMDA Receptor Antagonists Amantadine and Memantine: A Quantitative Microdialysis Study 1999 ·Pharmaceutical Research ·M.B. Hesselink, (unknown), D. D. Breimer, Wojciech Danysz	69
15	Adaptations of NMDA and dopamine D 2 , but not of muscarinic receptors following 14 days administration of uncompetitive NMDA receptor antagonists 1999 ·Journal of Neural Transmission ·M.B. Hesselink, Albertus G. de Boer, D. D. Breimer, Wojciech Danysz	13
16	Modifications of the behavioral profile of non-competitive NMDA receptor antagonists, memantine, amantadine and (+)MK-801 after chronic administration 1999 ·Behavioural Pharmacology ·M.B. Hesselink, (unknown), A.G. de Boer, D. D. Breimer, Wojciech Danysz	22
17	The Role of Probenecid-Sensitive Organic Acid Transport in the Pharmacokinetics of N-Methyl-d-Aspartate Receptor Antagonists Acting at the GlycineB-Site: Microdialysis and Maximum Electroshock Seizures Studies 1999 ·Journal of Pharmacology and Experimental Therapeutics ·M.B. Hesselink, (unknown), (unknown), A.G. de Boer, D. D. Breimer, Wojciech Danysz	19
18	Amino-alkyl-cyclohexanes are novel uncompetitive NMDA receptor antagonists with strong voltage-dependency and fast blocking kinetics: in vitro and in vivo characterization 1999 ·Neuropharmacology ·Chris G. Parsons, Wojciech Danysz, (unknown), (unknown), Tadeusz Frankiewicz, M.B. Hesselink, (unknown), G. Quack	113
19	Modulation of NMDA receptors by glycine ? introduction to some basic aspects and recent developments 1998 ·Amino Acids ·Chris G. Parsons, Wojciech Danysz, M.B. Hesselink, Sabine Hartmann, (unknown), (unknown), G. Quack	51
20	The Use of Intracerebral Microdialysis to Determine Changes in Blood-Brain Barrier Transport Characteristics 1995 ·Pharmaceutical Research ·Elizabeth C. M. de Lange, M.B. Hesselink, Meindert Danhof, Albertus G. de Boer, D. D. Breimer	25

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact